Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 3/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915139 | 0.87 | HTR7 (0.46) | SLC2A1HTR7TLR9DYRK1AGSK3B | |
| SCHEMBL914725 | 0.83 | TLR9 (0.44) | SLC2A1HTR7TLR9DYRK1AGSK3B | |
| SCHEMBL914569 | 0.83 | TLR9 (0.44) | SLC2A1HTR7TLR9DYRK1AGSK3B | |
| SCHEMBL914581 | 0.81 | GSK3B (0.42) | SLC2A1HTR7TLR9DYRK1AGSK3B | |
| SCHEMBL916126 | 0.79 | GSK3B (0.42) | SLC2A1HTR7TLR9DYRK1AGSK3B | |
| SCHEMBL915080 | 0.77 | BRD4 (0.49) | DYRK1AWNT1PARP1 | |
| SCHEMBL914089 | 0.76 | SLC2A1 (0.43) | SLC2A1TLR9DYRK1AGSK3BWNT1 | |
| SCHEMBL2762287 | 0.75 | GPR119 (0.51) | PARP1 | |
| SCHEMBL914740 | 0.74 | KDM4E (0.49) | HTR7DYRK1AHTR1A | |
| SCHEMBL914166 | 0.74 | DRD4 (0.44) | SLC2A1HTR7DYRK1AHTR1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | SLC2A1 820/4885HTR7 1237/4885TLR9 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.